A new study examines survival outcomes and CNS-related mortality among patients with ERBB2+ metastatic breast cancer (MBC) and central nervous system (CNS) disease. Among the 274 patients analyzed, 55.2% of deaths were attributed to CNS-related causes, with the highest risk in those with leptomeningeal disease (LMD).
Key findings include:
Patients with LMD had the shortest overall survival (OS) (1.24 years).
Patients with CNS-only disease had better survival outcomes (3.57 years) but still faced a high risk of CNS-related death.
Whole-brain radiotherapy was linked to an increased risk of CNS-related mortality.
These findings highlight the importance of aggressive local therapy for select patients with CNS-only disease to improve survival outcomes.
For more insights, explore the full study:https://lnkd.in/euwqvbx6).
